Inhibition of the Multiplication of Mycobacterium leprae by Vaccination with a Recombinant M. bovis BCG Strain That Secretes Major Membrane Protein II in Mice
Author(s) -
Yosuke Maeda,
Toshiki Tamura,
Masao Matsuoka,
Masahiko Makino
Publication year - 2009
Publication title -
clinical and vaccine immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.649
H-Index - 77
eISSN - 1556-6811
pISSN - 1556-679X
DOI - 10.1128/cvi.00203-09
Subject(s) - mycobacterium leprae , mycobacterium bovis , microbiology and biotechnology , recombinant dna , biology , vaccination , virology , interferon gamma , antigen , cd8 , inoculation , in vitro , mycobacterium tuberculosis , immunology , tuberculosis , leprosy , medicine , biochemistry , pathology , gene
The ability of a recombinantMycobacterium bovis BCG strain that secretes major membrane protein II (MMP-II) ofMycobacterium leprae (BCG-SM) to confer protection against leprosy was evaluated by use of a mouse footpad model. C57BL/6J mice intradermally inoculated with BCG-SM produced splenic T cells which secreted significant amounts of gamma interferon (IFN-γ) in response to either the recombinant MMP-II, theM. leprae -derived membrane fraction, or the BCG-derived cytosolic fraction in vitro more efficiently than those from the mice infected with the vector control BCG strain (BCG-pMV, a BCG strain containing pMV-261). A higher percentage of CD8+ T cells obtained from BCG-SM-inoculated mice than those obtained from BCG-pMV-inoculated mice produced intracellular IFN-γ on restimulation with theM. leprae antigens. BCG-SM inhibited the multiplication ofM. leprae in the footpads of C57BL/6J mice more efficiently than BCG-pMV. These results indicate that a BCG strain that secretes MMP-II could be a better vaccine candidate for leprosy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom